FOLH1 and prostate carcinoma: For example, 99mTc-MIP-1404 has shown efficacy in patients with intermediate- and high-risk prostate cancer undergoing prostatectomy and extended pelvic lymph node dissection (5) and has favorable radiation dosimetry (0.0088 mSv/MBq) compared with 68Ga-PSMA-11 (0.022 mSv/MBq) (13,14).